At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 150 enrolled
Drug / intervention
Gardasilbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Study of Gardasil in Human Papillomavirus Research The Mid-Adult Male Vaccine Study - The MAM STUDY
H. Lee Moffitt Cancer Center and Research Institute·interventional·Posted Sep 13, 2011·Updated Sep 16, 2021
In Brief
A Phase 2 clinical trial evaluating Gardasil for Human Papillomavirus. Completed, enrolled 150 participants across 2 sites in 2 countries.
Detailed Summary
The purpose of this study is to test the effectiveness of the research study vaccine, Gardasil, in men ages 27-45 who have completed 4 years of observation in The Human Papillomavirus \[HPV\] infection in men (HIM) Study.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Papillomavirus
CountriesMexico, United States
CollaboratorsMerck Sharp & Dohme LLC
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedSep 2011
Enrollment StartFeb 2013
Primary CompletionMay 2014
Study CompletionNov 2020
TodayJul 2026
First PostedSep 13, 2011
Enrollment StartFeb 19, 2013
Primary CompletionMay 23, 2014
Study CompletionNov 3, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 14.8 years ago
Interventions
Gardasilbiological
The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).